Auspex Secures $25M To Get To NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech garnered a $25 million Series D round, which could be enough to propel it through a Phase III trial and to FDA with its lead candidate. Investors are hoping an approved product could make Auspex an attractive take-out candidate.
You may also be interested in...
Concert Secures Celgene As Its Latest Partner
Concert Pharmaceuticals has garnered a third partnership for its deuterium-modification platform as the Massachusetts biotech continues to push its internal pipeline forward on its own.
Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round
Plus news on recent financings by Visterra, AbbVie, Pearl Therapeutics and Auspex.
No Obvious Prescription For Biopharma Investors
In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.